Spyre Therapeutics, Inc.
SYRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001636282
In the last 90 days, Spyre Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 265 institutions reported holding it in 13F filings for Q2 2026, worth $8.52B in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Spyre Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 67 | 55 | −12 |
| Shares | 49.4M | 44.7M | −4.69M (−9.5%) |
| Value | $24.8M | $23.5M | −$1.30M (−5.2%) |
New holders (3)
Institutions that held Spyre Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Sigma Securities, LLC | 31,043 | $16.0K | 0.00% |
| Ra Capital Management, L.P. | 10,439 | $5.00K | 0.00% |
| China Universal Asset Management Co., Ltd. | 573 | $0 | 0.00% |
Sold out (15)
Institutions that held Spyre Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Dimensional Fund Advisors LP | 506,326 | $255.0K |
| D. E. Shaw & Co., Inc. | 476,404 | $241.0K |
| Ergoteles LLC | 147,200 | $74.0K |
| UBS Group AG | 76,806 | $39.0K |
| Susquehanna International Group, LLP | 65,195 | $33.0K |
| Bridgeway Capital Management, LLC | 48,643 | $25.0K |
| Virtu Financial LLC | 31,151 | $16.0K |
| SG Americas Securities, LLC | 17,822 | $9.00K |
| Schonfeld Strategic Advisors LLC | 10,100 | $5.00K |
| Legal & General Group Plc | 3,264 | $2.00K |
| FMR LLC | 1,494 | $1.00K |
| New York State Common Retirement Fund | 341 | $0 |
| Credit Suisse AG | 21 | $0 |
| Advisor Group Holdings, Inc. | 470 | $0 |
| Lion Point Capital, LP | 300,000 | – |